Cohen H J, Pieper C F, Hanlon J T, Wall W E, Burchett B M, Havlik R J
Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina, USA.
Am J Med. 2000 Feb 15;108(3):210-5. doi: 10.1016/s0002-9343(99)00447-7.
We sought to explore the relation that has been previously reported between calcium channel blockers and an increased risk of cancer.
We followed 3,511 participants, age 65 years or older, in the Duke Established Populations for Epidemiologic Studies of the Elderly for up to 10 years. Information about use of medications was obtained at baseline and 3 and 6 years later. Information about hospitalization for cancer, or death from cancer, was obtained from Health Care Financing Administration data and death certificates.
Of the 133 users of calcium channel blockers, 16 (12%) developed cancer, compared with 548 (16%) of 3,378 nonusers (hazard ratio = 0.9; 95% confidence interval, 0.5 to 1.5). Adjusting for baseline and time-dependent covariates, such as race, diabetes, or blood pressure, for dose or class of calcium channel blockers, or for length of follow-up, had no effect.
Use of calcium channel blockers does not appear to be related to cancer risk. Earlier reports showing such a relation may have been the result of chance.
我们试图探究先前报道的钙通道阻滞剂与癌症风险增加之间的关系。
我们对杜克大学老年流行病学研究既定人群中3511名65岁及以上的参与者进行了长达10年的随访。在基线以及3年和6年后获取用药信息。关于癌症住院或癌症死亡的信息来自医疗保健财务管理局的数据和死亡证明。
在133名钙通道阻滞剂使用者中，16人（12%）患癌，而3378名非使用者中有548人（16%）患癌（风险比=0.9；95%置信区间，0.5至1.5）。对基线和时间依赖性协变量（如种族、糖尿病或血压）、钙通道阻滞剂的剂量或类别或随访时间进行调整均无影响。
使用钙通道阻滞剂似乎与癌症风险无关。早期显示这种关系的报告可能是偶然结果。
